The core value driver remains KT-621, Kymera’s STAT6-targeting program. “STAT6 remains [the] primary driver to the story,” ...

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the ...

Merck announced ACIP voted to recommend Enflosnia (clesrovimab-cfor) as a treatment option for RSV in infants younger than 8 months of age who are born during or entering their first RSV season.

The rapid adoption of the Omnipod 5 answered a question automated insulin delivery system manufacturers posed for years: with ...

Cineplex Inc . (TSX:CGX) stock rose 5% Friday after the company announced that longtime President and CEO Ellis Jacob will retire on December 31, 2026.

Boeing is entering a new phase of recovery that could support a market reassessment of its stock, according to analysts at Redburn.

Guggenheim raised its price target on Walt Disney (NYSE:DIS) Co to $140 from $120 on stronger-than-expected trends across sports advertising, theme parks, and progress on cost-cutting as the company ...

Kymera Therapeutics raises $250.8M in public offering to advance its innovative degrader medicines for immunological diseases.